---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000070"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:02:51.592430+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zentalis FY2024 cash $371.1M; azenosertib 34.9% ORR in PROC; cash runway to late 2027

## Summary
- Cash $371.1M; projected runway to late 2027. FY2024 op expenses $258.6M, down from $299.5M.
- Azenosertib monotherapy 34.9% ORR (n=43) in Cyclin E1+ PROC from DENALI Part 1b; mDOR 6.3 months.
- FDA Fast Track for azenosertib in PROC. DENALI Part 2 enrollment H1 2025, topline data by end 2026.
- New CEO Julie Eastland, CMO Ingmar Bruns, and other executives appointed in Nov 2024.
- Jan 2025 strategic restructuring to reduce costs; workforce reduction substantially complete Q2 2025.

## SEC filing metadata
- accession: 0001725160-25-000070
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/0001725160-25-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/zntl-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000070
- JSON: https://secwatch.observer/filing/0001725160-25-000070.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.